Clover has two manufacturing facilities – one focused on commercial manufacturing in Changxing, and another in Chengdu, suppling R&D and clinical programs.

Changxing Commercial Manufacturing Facility

We have an in-house, commercial-ready biologics manufacturing facility in Changxing, Zhejiang province, China. This facility will support the commercial production of SCB-2019.

Our Changxing facility adheres to the cGMP standards in accordance with the U.S., EU, and Chinese regulatory authorities.

In the third quarter of 2021, we received a Pharmaceutical Manufacturing Permit from the Zhejiang Medical Products Administration for the production of SCB-2019 (CpG 1018/Alum) at the Changxing manufacturing facility.

Chengdu R&D and Pilot Manufacturing Facility

Our R&D and pilot manufacturing facility is located in Chengdu, Sichuan province, China and supplies materials for our pre-clinical, IND, and early-stage clinical trials. The facility site occupies approximately 3,300 sq.m and contains a 200L single-use and 150L stainless steel bioreactor capacity as well as multiple pilot-scale drug product (DP) filling lines. The Chengdu manufacturing facility will continue to supply materials for pre-clinical studies and early-stage clinical trials and support product candidate development.